Toggle Main Menu Toggle Search

Open Access padlockePrints

Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia

Lookup NU author(s): Dr Claire Wood, Professor Volker StraubORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Short stature and osteoporosis are common in Duchenne muscular dystrophy (DMD) and its pathophysiology may include an abnormality of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, which is further exacerbated by long-term glucocorticoid (GC) treatment. Hence, an agent that has anabolic properties and may improve linear growth would be beneficial in this setting and therefore requires further exploration. A 5-week-old x-linked muscular dystrophy (mdx) mice were used as a model of DMD. They were treated with prednisolone ± GH + IGF-1 for 4 weeks and then compared to control mdx mice to allow the study of both growth and skeletal structure. GC reduced cortical bone area, bone fraction, tissue area and volume and cortical bone volume, as assessed by micro computed tomography (CT) In addition, GC caused somatic and skeletal growth retardation but improved grip strength. The addition of GH + IGF-1 therapy rescued the somatic growth retardation and induced additional improvements in grip strength (16.9% increase, P < 0.05 compared to control). There was no improvement in bone microarchitecture (assessed by micro-CT and static histomorphometry) or biomechanical properties (assessed by three-point bending). Serum bone turnover markers (Serum procollagen 1 intact N-terminal propeptide (P1NP), alpha C-terminal telopeptide (αCTX)) also remained unaffected. Further work is needed to maximise these gains before proceeding to clinical trials in boys with DMD.

Publication metadata

Author(s): Wood CL, van 't Hof R, Dillon S, Straub V, Wong SC, Ahmed SF, Farquharson C

Publication type: Article

Publication status: Published

Journal: Journal of Endocrinology

Year: 2022

Volume: 253

Issue: 2

Pages: 63-74

Print publication date: 01/05/2022

Online publication date: 29/03/2022

Acceptance date: 21/02/2022

Date deposited: 25/04/2022

ISSN (print): 0022-0795

ISSN (electronic): 1479-6805

Publisher: Bioscientifica Ltd


DOI: 10.1530/JOE-21-0388

PubMed id: 35191394


Altmetrics provided by Altmetric


Funder referenceFunder name